Company focused on immune modulation for the treatment of several specific diseases, Therapeutic Solutions International (OTCMKTS:TSOI), on July 27, 2021 reported preliminary data showing administration of JadiCell, its universal donor adult stem cell product, reducing pulmonary pathology.
This replicates severe inflammation seen in patients infected with covid-19 delta variant. In a number of experiments done, mice were given a synthetic version of viral compounds, which are seen to damage lungs akin to covid.
The present experiment harnessed significantly higher doses of viral mimicking compounds. Studies have published that the variant evades different types of body immune mechanisms, resulting in higher viral load as compared to the original virus.
Dr.James Veltmeyer, Chief Medical Officer of the Company, said that not much known is known about the data variant and even though the data was based on animal studies, the suppression of lung damage, not seen in other stem cells, supports idea of Jadicell benefitting patients.
Jadicell has been successful in ameliorating survival in end-stage patients of covid induced lung failure in an FDA double blind, placebo controlled clinical trial.
Timothy Dixon, President and CEO of the Company, said that the company is committed on learning about cellular product from laboratory studies. Dixon added that JadiCell’s unique ability to suppress cytokine storm and stimulating regenerative processes in the lung,makes it a hope of being a weapon in the fight against covid-19.
 Stock Moves in a Range: What Next?){kind=link}